AstraZeneca could benefit from COVID-19 antibody as right on time as July Kumar Jeetendra | October 8, 2020 AstraZeneca could start profiting from the COVID-19 vaccine as soon as July next year, the Financial Times reported Wednesday, citing a memo showing the British drugmaker can declare when it considers the pandemic to have ended. The London-listed firm previously said it wouldn’t profit from the vaccine”during the pandemic”, and the report attributes the development …
India decays proposition to test Russia’s COVID-19 immunization Sputnik-V in huge examination Kumar Jeetendra | October 8, 2020 India’s drug regulator has knocked back a proposal from Dr Reddy’s Laboratories Ltd to conduct a large study in the nation to evaluate Russia’s Sputnik-V COVID-19 vaccine and has asked it to test the vaccine in a smaller trial. The recommendations by an expert panel of the Central Drugs Standard Control Organisation (CDSCO) noted that …
World’s quickest UV camera records photons progressively Kumar Jeetendra | October 8, 2020 Compressed ultrafast photography (CUP) captures the whole process in real time and unparalleled resolution with only one click. The spatial and temporal information is compressed into a picture and then, with a reconstruction algorithm, it is converted into a movie. Developing a compact instrument for UV Until now, this technique was limited to visible and …
Indo-Israel fast COVID-19 testing examination to fructify in ‘matter of days’: Israeli agent Kumar Jeetendra | October 9, 2020 A game-changer rapid COVID-19 testing technologies being jointly developed by India and Israel should be prepared for rollout in”a matter of days” and it’ll have the ability to give test results in less than a minute by simply requiring an individual to blow into a tube, the Israeli envoy to India has stated. Ambassador Ron …
China says will buy COVAX immunizations for 1% of populace Kumar Jeetendra | October 9, 2020 China will purchase COVID-19 vaccines for just 1 percent of its population, or 15 million people, via a global scheme backed by the World Health Organization, the Foreign Ministry said on Friday. Beijing’s move to join the COVAX programme means China”will be procuring vaccines through the facility for a percentage of their own population, just …
Researchers identify enduring antibodies in blood, spit tests from COVID-19 patients Kumar Jeetendra | October 9, 2020 Scientists, including among Indian-origin, have documented the persistence of antibodies that target the novel coronavirus from the blood and saliva of patients with COVID-19 at least three months after symptom onset, a finding that may lead to alternate methods of testing for the viral infection. The study, published in the journal Science, points to the …
Takeda-drove COVID-19 plasma treatment enters clinical preliminary with first patient Kumar Jeetendra | October 9, 2020 Japan’s Takeda Pharmaceutical Co said on Friday an alliance of drugmakers that it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays. The phase 3 trial from the group, referred to as the CoVIg Plasma Alliance, intends to enroll 500 adult …
Compact, High Resolution Chromatography Flowmeter Kumar Jeetendra | October 9, 2020 TESTA Analytical Solutions e.K. has developed a new flowmeter which enables continuous measurement of flow rate without interference in chromatography systems. Flow rate is one of the most important parameters in any liquid chromatography system, it determines retention time or volume and has by nature a major influence on reproducibility. Compatible with all HPLC and …
New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
INTEGRA’s VOYAGER adjustable tip spacing electronic pipette: Increase workflow efficiency Kumar Jeetendra | October 10, 2020 Korcan Ayata is a member of the gastroenterology group – led by Prof. Dr Jan Niess – which focuses on researching mucosal immunology and gastroenterology. The group is interested in the role of immune cells in inflammatory conditions, studying how monocytes enter the tissue and differentiate into macrophages to have pro- or anti-inflammatory effects during …
High-dosage favipiravir ‘strong’ against COVID-19, HCQ totally incapable: Study Kumar Jeetendra | October 11, 2020 Research conducted at the KU Leuven Rega Institute in Belgium has found that the antimalarial drug hydroxychloroquine (HCQ) doesn’t limit the multiplication of the novel coronavirus. However, a very high dose of the flu drug favipiravir does have antiviral efficacy, according to their results. The researchers gave the hamsters either hydroxychloroquine or favipiravir for four …
